Latest T helper cell Stories

WORCESTER, Mass. and TORONTO, April 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that the American Association for Cancer Research (AACR) chose to spotlight a presentation on data from the ongoing clinical trial of AE37, an immunotherapeutic vaccine to prevent relapse in patients who have had breast cancer being developed by Antigen Express, in a press conference. The annual AACR meeting is one of the largest national cancer conferences...

The characterisation of a rare immune cell’s involvement in antibody production and ability to ‘remember’ infectious agents could help to improve vaccination and lead to new treatments for immune disorders, say researchers from the Walter and Eliza Hall Institute. The cells, called T follicular helper cells, represent less than half of one per cent of all immune cells, but play a critical role in antibody production and developing long-lasting immunity. However, the cells are also...

The hallmark loss of helper CD4+ T cells during human immunodeficiency virus (HIV) infection may be a red herring for therapeutics, according to a study published on March 26th in the Journal of Experimental Medicine. HIV preferentially infects CD4+ T cells, immune cells required to generate protective antibodies. In many people, this leads to a progressive drop in CD4+ T cell numbers—and the more the numbers fall, the faster AIDS develops. HIV-induced cell loss includes both 'naive'...

Using data from the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), Jim Young and colleagues from The Opportunistic Infections Project Team of COHERE show in this week's PLoS Medicine that in successfully treated patients, the risk of a new AIDS event or death follows a CD4 cell count gradient in patients with viral suppression. An increase in CD4 cell count provides the greatest benefit for patients with a CD4 cell count below 200 cells/µL but still provides...

WORCESTER, Mass. and TORONTO, March 14, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that a review of the Antigen Express proprietary platform technology for generation of immunotherapeutic vaccines has been published in the peer-reviewed journal Vaccine. The Company is developing therapeutic vaccines for serious unmet medical needs, such as cancer. The article, entitled "CD4+ T-cell activation for immunotherapy of malignancies using...

Some monkeys can survive infection by SIV, a relative of HIV, and not develop AIDS. Their immune systems appear to display a pattern of "peaceful coexistence" rather than the all-out conflict provoked by HIV when it infects humans. SIV's natural hosts are non-human primates found in central Africa, including sooty mangabeys and African green monkeys – both species whose SIV infections have been studied in captivity -- as well as other species such as mandrills, drills and suntailed...

BRISBANE, Calif., March 5, 2012 /PRNewswire/ -- SARcode Bioscience, Inc., a privately held biopharmaceutical company, announced today that it has completed patient enrollment in their first pivotal Phase 3 clinical study (OPUS-1) of SAR 1118 ophthalmic solution. SAR 1118 is a first-in-class small-molecule integrin antagonist that inhibits T-cell inflammation by blocking the binding of two key surface proteins (LFA-1 and ICAM-1) that mediate the chronic inflammatory cascade...

(Ivanhoe Newswire) – Good news! Researchers have discovered a promising new technique that potentially could turn immune system killer T cells into more effective weapons against infections and possibly cancer. “The technique involves delivering DNA into the immune system's instructor cells. The DNA directs these cells to overproduce a specific protein that jumpstarts important killer T cells, called CD8 T cells. These killer cells are typically repressed in patients who have HIV or...

WORCESTER, Mass. and TORONTO, Feb. 27, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT.OB) announced today that Dr. Eric von Hofe, Ph.D., President of Generex subsidiary Antigen Express, Inc., will give a presentation at the upcoming Cancer Immunotherapy Summit to be held in Boston, MA February 27-29. The presentation, entitled "Recent Advances in Understanding the Immune System and the Role of Th cells," will be given Wednesday, February 29 at 9:45 am EST....